Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph
uniQure’s stock performance in 2025 has been remarkably strong, capped by the explosive move on Sep. 24 after the Huntington’s data release. Prior to the announcement, QURE was trading in the mid-teens ts2.tech – already up over 100% year-to-date as anticipation for the trial results built. When the pivotal results hit, trading was halted pre-market due to pending news ts2.tech. Once the halt lifted, the stock opened dramatically higher and at one point reached the mid-$40s per share, up nearly 160–200% in a single session pharmaphorum.com. It eventually closed with a gain of around 150%+ on the day investing.com. This massive one-day jump is one of the biotech sector’s biggest of 2025, reflecting how transformational the news was for uniQure’s outlook. Such a rally vastly increased uniQure’s market capitalization – from roughly $750–800 million before the data to about $2.5–3 billion afterward finance.yahoo.com. Even after this surge, analysts note the valuation still “assigns limited credit” for AMT-130’s full potential ts2.tech. At ~$2.5B market cap, investors are pricing in some probability of success, but not the entirety of a Huntington’s gene therapy addressable market which could translate to blockbuster revenues if approved ts2.tech. For context, Bluebird Bio – another gene therapy
